Tempus AI raised its full-year guidance after reporting a 22% revenue increase in the second quarter of 2026 and improved profit margins, despite ongoing operating losses. Oncology testing volumes rose 31% year over year, while MRD testing nearly doubled from the fourth quarter of 2025. The results supported the company's acquisition of Personalis, which addresses a gap in minimal residual disease monitoring, and its data and applications segment grew 28% in Q2. Tempus AI's stock surged 60%.